We believe women should have access to the most effective medicines, regardless of their diverse needs. As we choose products for development and study them in robust clinical trials, we tackle areas where many women struggle with limited medicine choices. We are always looking for new products and partnerships to help fulfill this mission and welcome expressions of interest.
The power to avoid unintended pregnancy is essential to women’s health. We chose our first product, a long-acting, reversible contraceptive (LARC), because many women still face barriers in accessing the full range of contraceptive options.
Our ACCESS IUS trial, the largest of its kind in the U.S., was designed to measure the safety and efficacy of our product in women across a range of ages, body mass indexes, parous and nulliparous states (whether or not a woman had given birth), ethnic backgrounds and locations. Women and health care professionals need access to products designed to reflect patients’ diverse needs, so our product was designed with input from healthcare professionals working in different settings.
Our product, a hormonal intrauterine system (IUS or IUD), was granted initial FDA approval in February 2015, and supplemental approvals in September 2016 and August 2017.
For additional safety information on our first product, see full Prescribing Information